Navigation Links
Carrington Reports on ISO 9001:2000 Inspection
Date:11/14/2007

- Company's Quality Commitment Continues

- Undisrupted Distribution of CE Marked Products in European Union

IRVING, Texas, Nov. 14 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (OTC Bulletin Board: CARN) today announced that the Company has completed its annual ISO 9001:2000 re-certification inspection at its Irving, Texas location. The inspection was performed by the European Union's notified body, AMTAC Certification Services, Ltd., a division of Intertek Systems Certification. Earlier in 2007, Carrington's wholly-owned subsidiary in Costa Rica, Sabila Industrial, completed its ISO 9001:2000 re-certification inspection.

Dr. Carlton Turner, president and CEO, stated, "Carrington invests a great amount of resources to ensure its quality standards are upheld. Our quality teams in the U.S. and Costa Rica continue to focus on maintaining and improving the Company's quality systems, which defines the standards of all of our raw materials and finished products.

Sabila Industrial manufactures GelSite(R) polymer, the raw material key to the drug and vaccine delivery technology being developed by Carrington's biotech subsidiary DelSite Biotechnologies, Inc. GelSite(R) is the key polymer to formulate the GelVac(TM) influenza nasal powder vaccine for bird flu (H5N1).

Turner continued, "DelSite's vaccine program and working relations with other bio and pharma companies is based on quality in our manufacturing and development areas. Having all formulations and products developed in an ISO facility and under cGMPs provides a solid foundation for future growth of DelSite and our core business."

Carrington's international customer base includes companies who distribute Carrington products in areas of countries such as Italy, France, Portugal, Serbia-Montenegro; with the expansion into countries such as Cypress, Poland and Turkey.

About Carrington

Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com.

Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission.


'/>"/>
SOURCE Carrington Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
2. Carrington Reports Second Quarter 2007 Results
3. Carrington Completes $8 Million Financing
4. Carrington Reports on ISO 9001:2000 Inspection at Sabila Industrial in Costa Rica
5. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
6. Carrington and DaySpring Pharma Extend and Formalize Agreement for Distribution of Diabetic and Radiation Products Into Physician Market
7. Carrington Laboratories Common Stock Now Trading on the OTC Bulletin Board: CARN.OB
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Jan. 17, 2017  Protagonist Therapeutics, Inc. (NASDAQ: ... has initiated a global Phase 2b induction study ... that targets alpha4beta7 integrin. The aim of this ... evaluate the safety/tolerability and efficacy of PTG-100 in ... to severe active disease. "We ...
(Date:1/16/2017)... , Jan. 16, 2017   Valentin A. Pavlov, ... MD , president and CEO of The Feinstein ... an analysis of how the nervous system regulates the ... develop bioelectronic medicine devices to treat disease ... Nature Neuroscience . The paper examines various ...
(Date:1/14/2017)... ... January 14, 2017 , ... Seattle-based Phase ... end-to-end genome assemblies to researchers around the globe. Long considered a “holy ... answering a wide range of scientific questions. The announcement was made today ...
(Date:1/13/2017)... Research and Markets has announced the addition of the "Global Biopolymers ... ... of 16.83% during the period 2017-2021. The report covers ... for 2017-2021. To calculate the market size, the report considers the revenue ... includes a a discussion of the key vendors operating in this market. ...
Breaking Biology Technology:
(Date:12/15/2016)... FREMONT, Calif. , Dec. 15, 2016   ... a publicly held genomics technology company, announced today that ... the Listing Qualifications Department of The Nasdaq Stock Market ... the closing bid price of WaferGen,s common stock had ... days.  Accordingly, WaferGen has regained compliance with Listing Rule ...
(Date:12/15/2016)... LONDON , Dec. 15, 2016 /PRNewswire/ ... the driving experience, health wellness and wellbeing ... As one in three new passenger vehicles ... voice recognition, gesture recognition, heart beat monitoring, ... eyelid monitoring, facial monitoring, and pulse detection. ...
(Date:12/15/2016)... "Increase in mobile transactions is driving the growth of ... expected to grow from USD 4.03 billion in 2015 ... of 29.3% between 2016 and 2022. The market is ... smart devices, government initiatives, and increasing penetration of e-commerce ... to grow at a high rate during the forecast ...
Breaking Biology News(10 mins):